Safety, Effectiveness, and Cost-effectiveness of Argus II in Patients with Retinitis Pigmentosa: a Systematic Review

Overview

Journal Int J Ophthalmol

Specialty Ophthalmology

Date 2021 Feb 22

PMID 33614463

Citations 6

Authors

Zakieh Ostad-Ahmadi

Amin Daemi

Mohammad-Reza Modabberi

Ali Mostafaie

Affiliations

Soon will be listed here.

Abstract

Aim: To assess the effectiveness, safety, and cost-effectiveness of the Argus II in treatment of the retinitis pigmentosa (RP) patients.

Methods: The ProQuest, Web of Science, EMBASE, MEDLINE ( PubMed) were searched using combinations of the keywords of Argus, safety, effectiveness, bionic eye, retinal prosthesis, and RP through March 2018. The retrieved records were screened and then assessed for eligibility.

Results: Totally 926 records were retrieved from the searched databases and finally 12 studies included. The RP patients showed improvements in visual function after receiving the prosthesis, compared to the time before the prosthesis or the time it was off. This was measured by square localization, direction of motion, and grating visual acuity tests. No major adverse effect was reported for the Argus II prosthesis itself and/or the surgery to implement it, but the most frequently reported items were hypotony, and conjunctival dehiscence. The incremental cost-effectiveness ratio (ICER) was calculated to be €14603 per quality-adjusted life year (QALY) in UK and $207 616 per QALY in Canada.

Conclusion: The available evidence shows that the Argus II prosthesis in RP patients is effective in improvement of their visual function. Some minor adverse effects are reported for the prosthesis. The cost-effectiveness studies show that the technology is cost-effective only at high levels of willingness-to-pay.

Citing Articles

A Second-Generation (44-Channel) Suprachoroidal Retinal Prosthesis: A Single-Arm Clinical Trial of Feasibility.

Petoe M, Abbott C, Titchener S, Kolic M, Kentler W, Nayagam D Ophthalmol Sci. 2024; 5(1):100525.

PMID: 39328823 PMC: 11426041. DOI: 10.1016/j.xops.2024.100525.

Retinitis Pigmentosa and Therapeutic Approaches: A Systematic Review.

Confalonieri F, La Rosa A, Ottonelli G, Barone G, Ferraro V, Di Maria A J Clin Med. 2024; 13(16).

PMID: 39200821 PMC: 11355744. DOI: 10.3390/jcm13164680.

PRPF31-retinitis pigmentosa: Challenges and opportunities for clinical translation.

Aweidah H, Xi Z, Sahel J, Byrne L Vision Res. 2023; 213:108315.

PMID: 37714045 PMC: 10872823. DOI: 10.1016/j.visres.2023.108315.

Pars Plana Vitrectomy in Inherited Retinal Diseases: A Comprehensive Review of the Literature.

Iovino C, Rosolia A, Damiano L, Iodice C, Di Iorio V, Testa F Life (Basel). 2023; 13(6).

PMID: 37374028 PMC: 10305349. DOI: 10.3390/life13061241.

Gene-agnostic approaches to treating inherited retinal degenerations.

Chew L, Iannaccone A Front Cell Dev Biol. 2023; 11:1177838.

PMID: 37123404 PMC: 10133473. DOI: 10.3389/fcell.2023.1177838.

References

. Retinal Prosthesis System for Advanced Retinitis Pigmentosa: A Health Technology Assessment. Ont Health Technol Assess Ser. 2016; 16(14):1-63. PMC: 4947979. View

da Cruz L, Dorn J, Humayun M, Dagnelie G, Handa J, Barale P . Five-Year Safety and Performance Results from the Argus II Retinal Prosthesis System Clinical Trial. Ophthalmology. 2016; 123(10):2248-54. PMC: 5035591. DOI: 10.1016/j.ophtha.2016.06.049. View

Barry M, Dagnelie G . Use of the Argus II retinal prosthesis to improve visual guidance of fine hand movements. Invest Ophthalmol Vis Sci. 2012; 53(9):5095-101. PMC: 3416020. DOI: 10.1167/iovs.12-9536. View

Kotecha A, Zhong J, Stewart D, da Cruz L . The Argus II prosthesis facilitates reaching and grasping tasks: a case series. BMC Ophthalmol. 2014; 14:71. PMC: 4039311. DOI: 10.1186/1471-2415-14-71. View

Hahm B, Shin Y, Shim E, Jeon H, Seo J, Chung H . Depression and the vision-related quality of life in patients with retinitis pigmentosa. Br J Ophthalmol. 2008; 92(5):650-4. DOI: 10.1136/bjo.2007.127092. View

Vaidya A, Borgonovi E, Taylor R, Sahel J, Rizzo S, Stanga P . The cost-effectiveness of the Argus II retinal prosthesis in Retinitis Pigmentosa patients. BMC Ophthalmol. 2014; 14:49. PMC: 3990272. DOI: 10.1186/1471-2415-14-49. View

Ho A, Humayun M, Dorn J, da Cruz L, Dagnelie G, Handa J . Long-Term Results from an Epiretinal Prosthesis to Restore Sight to the Blind. Ophthalmology. 2015; 122(8):1547-54. PMC: 4516690. DOI: 10.1016/j.ophtha.2015.04.032. View

Hartong D, Berson E, Dryja T . Retinitis pigmentosa. Lancet. 2006; 368(9549):1795-809. DOI: 10.1016/S0140-6736(06)69740-7. View

Duncan J, Richards T, Arditi A, da Cruz L, Dagnelie G, Dorn J . Improvements in vision-related quality of life in blind patients implanted with the Argus II Epiretinal Prosthesis. Clin Exp Optom. 2016; 100(2):144-150. PMC: 5347867. DOI: 10.1111/cxo.12444. View

10.

Rizzo S, Belting C, Cinelli L, Allegrini L, Genovesi-Ebert F, Barca F . The Argus II Retinal Prosthesis: 12-month outcomes from a single-study center. Am J Ophthalmol. 2014; 157(6):1282-90. DOI: 10.1016/j.ajo.2014.02.039. View

11.

da Cruz L, Coley B, Dorn J, Merlini F, Filley E, Christopher P . The Argus II epiretinal prosthesis system allows letter and word reading and long-term function in patients with profound vision loss. Br J Ophthalmol. 2013; 97(5):632-6. PMC: 3632967. DOI: 10.1136/bjophthalmol-2012-301525. View

12.

Kang K, Tarchick M, Yu X, Beight C, Bu P, Yu M . Carnosic acid slows photoreceptor degeneration in the Pde6b(rd10) mouse model of retinitis pigmentosa. Sci Rep. 2016; 6:22632. PMC: 4785376. DOI: 10.1038/srep22632. View

13.

Humayun M, Dorn J, da Cruz L, Dagnelie G, Sahel J, Stanga P . Interim results from the international trial of Second Sight's visual prosthesis. Ophthalmology. 2012; 119(4):779-88. PMC: 3319859. DOI: 10.1016/j.ophtha.2011.09.028. View

14.

Dorn J, Ahuja A, Caspi A, da Cruz L, Dagnelie G, Sahel J . The Detection of Motion by Blind Subjects With the Epiretinal 60-Electrode (Argus II) Retinal Prosthesis. JAMA Ophthalmol. 2013; 131(2):183-9. PMC: 3924899. DOI: 10.1001/2013.jamaophthalmol.221. View

15.

Luo Y, Zhong J, da Cruz L . The use of Argus® II retinal prosthesis by blind subjects to achieve localisation and prehension of objects in 3-dimensional space. Graefes Arch Clin Exp Ophthalmol. 2014; 253(11):1907-14. DOI: 10.1007/s00417-014-2912-z. View